Keywords: Europe, Patent settlements, Pay-to-delay, EFPIA, European Commission

EU Commission welcomes decrease of potentially problematic patent settlements in EU pharma sector, but EFPIA sees no “discernible trend”

Article | 06 July 2010

The number of patent settlements in the pharmaceutical sector that are potentially problematic under the European Union's antitrust rules fell ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in